Major providers AT&T and Verizon both said it was an industry-wide problem and referred comment Friday to an industry trade ...

Aucatzyl is a CAR T-cell therapy that targets CD19 and has been designed to minimize excessive activation of the programmed T ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

Mobile’s fixed wireless service for two years. It’s superior to DSL but has some quirks I've discovered along the way.

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Craig A. Portell, MD, discusses the current standard of care for patients with relapsed/refractory mantle cell lymphoma and how sequencing therapies changed the landscape of mantle cell lymphoma ...

After selling to T-Mobile and Verizon, US Cellular has sold another chunk of its spectrum to AT&T now. Here’s what it could ...

AT&T will buy UScellular spectrum including 3.45 GHz and 700 MHz for $1 billion, as the latter prepares to sell its wireless ...

Verizon and AT&T both said the fines violate their Seventh Amendment right to a jury trial, and that the location data ...

Approval of the CD19 chimeric antigen receptor T-cell therapy (CAR T) — which, according to Autolus, was specifically “designed to have a ‘fast-off’ kinetic” to minimize excessive activation of the ...

United States Cellular said today it has agreed to sell a portion of spectrum licenses used to transmit mobile phone signals and high-speed data services to AT&T in a $1.02 billion deal. The ...